Abstract

The approaches of combining analytical and pharmacokinetic tools can currently assist clinicians in routinely providing more effective and individualized treatment, including in complicated cases of pediatric acute myeloid leukemia. Anticancer drug dosing based on synchronized drug monitoring and pharmacokinetic analysis can provide a better estimation of the drug systemic exposure than that obtained with the stable dosing plan. Leukemia is difficult to treat and, in the case of children, has the most dramatic and tragic course. Therefore, it is important to search for new biomarkers of leukemia that will enable early diagnosis. Hence, a completed strategy with chromatographic methods as the core element of analytical procedures provides an efficient tool that is beneficial for clinicians involved in the treatment and diagnosis of leukemia.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call